FMP
Adial Pharmaceuticals, Inc.
ADIL
NASDAQ
Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its lead product is AD04, a selective serotonin-3 antagonist, which is in Phase III clinical trial for the treatment of alcohol use disorder. The company also focuses on developing drug candidates for non-opioid pain reduction and other diseases and disorders. Adial Pharmaceuticals, Inc. was founded in 2010 and is based in Charlottesville, Virginia.
1.08 USD
0.07 (6.48%)
We are unable to load the chart at this time.
Mr. Cary John Claiborne MBA
Healthcare
Biotechnology
NASDAQ
Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its lead product is AD04, a selective serotonin-3 antagonist, which is in Phase III clinical trial for the treatment of alcohol use disorder. The company also focuses on developing drug candidates for non-opioid pain reduction and other diseases and disorders. Adial Pharmaceuticals, Inc. was founded in 2010 and is based in Charlottesville, Virginia.
0001513525
US00688A2050
00688A106
1180 Seminole Trail
434 422 9800
US
4
Jul 27, 2018
We are unable to load the chart at this time.
We are unable to load the chart at this time.
0001513525
NASDAQ
Biotechnology
Healthcare
00688A106
US00688A2050
US
1.08
1.3
178.5k
6.99M
-
0.77-4.17
1.98
-
-
-
-
-0.37
-
https://www.adialpharma.com
We are unable to load this data!
Financial Information
Financial Summary Real-Time Price
Financial Statements
Financial Quarter Statements
Ratios Analysis
Dupont Analysis
Free Cashflow
Operating Data
Balance Sheet Data
Financial Modelling
Discounted Cashflow Model
Discounted Cashflow Model Levered
Free Cashflow Build-Up
Terminal Value
Intrinsic Value
Weighted Average Cost of Capital
Market Information
Stock Value
It looks like there's no news available.